Member Info for Mikemine

I've watched small companies in this sector and it's painfully slow to get traction. Doctors are notoriously conservative and are often difficult to shift to something new. Maybe the younger ones are more accepting of novelty.

Barrington summed up the process well in yesterday's presentation and it's not that straight forward. VRCI are getting there and hopefully the figures will show that for the next 2 quarters. They've set themselves a high target which, if they can bring it off, will be some achievement for a shoestring company.

405mn shares. When Tempus gets going and coupled with RENX's salesforce's addition can you believe the company won't be valued at over £400mn? £200mn maybe? £100mn maybe? Anyway you look at it this company is on track for a multi-bagger.

If in doubt, just look at VRCI's podcast when it comes out. It's run on a shoestring but the latest fundraise enabled it to hire 2 new salespeople, trebling the salesforce would you believe. They are already witnessing a big uplift in sales orientated revenue activity. It's early days with them on their commercialisation path but it's looking good. Relate that action to what will happen with RENX and you have some idea of the possible trajectory of the valuation.

Both companies are well undervalued IMHO but it looks like the MMs want both SPs to trade within a certain bands so they can earn a turn easily. It can't last forever.

I'm really surprised nobody has commented on the Investor's Presentation.

I've seen no mention of Powell here so far but he is a great addition to the board and will no doubt guide VRCI to create value and presence in the Market.

VRCI is certainly punching above its weight on a shoestring budget. They are certainly doing what they said they would and going all out for sales.

On Paige's website it says the CEO is Rasik Yousfi. How did you come up with McCullough?

https://www.healthcareittoday.com/2025/03/20/how-ai-is-advancing-cancer-diagnosis/

Why have you not corrected your inflammatory statement that the CEO of RENX has sold out to Tempus?

I really don't understand what is happening regarding UBS. I can't recollect seeing anything like it before.

I don't think anybody can deny that this RNS is anything but positive. My slant is that this points to a more international thinking for RENX. It's long term no doubt but we can see the big boys interest being more than tweaked otherwise why go for the CE mark. One to keep an eye on definitely.

Meanwhile back in the States things are more advanced with the Tempus deal, which don't forget is huge for company RENX's size, we anticipate an upgrade in the revenue forecasts. All positive in my book yet the MMs choose to play their games. I've tucked my shares away for the long term as I can see a big future here if they get things right. Just my opinion.

Some big trades today. Goodness knows what is going on.

Beat me to it Ramp.

I thought the threshold was 3%. Am I wrong?

Interesting thoughts G_G_G but I don't think you've factored in the enterprise value nor investors eagerness to pile in to a success story with plenty of legs. 2027 is a very long way off for RENX and we haven't even factored in any other possible collaborations but, if they can pull off all we hope for, and the Tempus deal is an indication of their ability to do so, then I see a billion pound company at some stage. Lots of if's a but's here but then that's investing for you.

Not advice, just opinion.

What we will get next week for sure is a lot more shares in the Market. I'd imagine the placing shares will not be traded but some or retail shares might well be off loaded for a tiny profit. On the other hand retail investors who have money returned as their full applications have not been filled will have funds available to buy shares near the offer price. My guess is that there will be continued buying and if the MMs take the brakes off, which they seem very reluctant to do, the SP should go in to positive territory.

As for a RNS about an updated revenue forecast, I hope next week but I'll be happy whenever we get it as long as it is a marked upgrade. I'm sure there will be estimates from other posters so the comments board should be quite active and interesting.

The emphasis within the NHS according to Wes Streeting at least, is changing from management of condition to prevention. That sounds good and right but it needs a culture and mind set change within the NHS at all levels. The problem with the change is that there are up front costs, in our case funding mass testing and subsequent drug payments all before you get the better outcomes and big savings. We think it would be worth it and I would venture most of the population would also agree but then you go back to that NHS thinking and would the Chancellor give the extra funding?

Anyway approaching the NHS is some way off, unless Tempus is here already, so we need the numbers in America to pile up, or at least be forecast to, to get some SP traction.

Thanks for the calculations Ramptastico.

Totally agree but without guidance on pricing what can you go by. The NHS will drive a hard bargain but even around £300-£400 it sounds pricey to me. It's certainly not going to be as cheap as a PSA for example. Whether the NHS will see it as value for money, and I think it should be at even £700, remains to be seen but I don't hold out much hope. It's only an opinion.

Personally, if I had been a diabetic for a while I'd pay for the test myself but I can, others maybe not so much.

The relevant physician number is interesting. I've been over in the States quite a few times staying with a relation so I get to see some idea of what goes on when they have to have medical assistance occasionally. It's a bit different from here. Most people I came across have health insurance and the GPs are more geared up to ordering tests. It's one of the characteristics of their healthcare system. I think they over order tests to avoid possible litigation if things go wrong.

Anyhow, I'm not sure how many Physicians would use this test or to what extent but my experience over there would suggest primary care GPs would be included in that number. Over here? The test would be a bit pricey for the GP market I reckon and that's where is would be most valuable in picking up hidden problems. It a bit early to talk of the NHS I think.

I was wondering that myself Megan. I can only think they are building this stake on behalf of a 3rd Party and then transferring the shares over to them but it has been happening a few times now. It does look odd though.

Yet again the SP drops when the buys vastly outnumber sells; getting on for 3:1. This is a corrupt market.

Over £1mn bought and only £417,000 sold and the SP down 7%. If that's not manipulation of the Market I don't know what is. No wonder AIM has such a bad name.